A rare case of metastatic atypical meningioma that highlights the shortcomings of treatment options at present

Erik Kristian Maurice Wrange*, Stefan Markus Walbom Harders

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

5 Downloads (Pure)


We report a case of a locally invasive recurrent atypical meningioma in the temporal region with late onset of meningioma lung metastasis. The patient was diagnosed in early adolescence with an atypical meningioma believed to be radiotherapy induced following treatment of a benign pilocytic astrocytoma in the hypothalamus region at 6 years of age. Even though the patient underwent several surgical and radiotherapy treatments, the intracranial meningioma kept growing and was locally invasive. The patient received experimental treatment with bevacizumab, a vascular endothelial growth factor A (VEGF-A)-inhibitor, for 4 years from age 26. Treatment was withdrawn after proven tumor growth on routine control MRI. A DOTA-TOC PET-CT-scan was performed to evaluate the DOTA-TOC somatostatin receptor number for possible SSTR (somatostatin receptor targeted therapy). In the included scan plan multiple lung metastasis were detected and later verified. Genomic tumor sequencing was performed, but no targeted treatment options were found. Instead, the patient finally, as the last treatment option, underwent 4 series of SSTR-targeted therapy (Lutetium DOTA-TOC). Unfortunately, the intracranial tumor component significantly progressed during the final stages of the treatment and the patient died less than a year after treatment was withdrawn at age 32. This case story illustrates the shortcomings of atypical/anaplastic meningioma treatment strategies at present and highlights the possibility of extracranial metastasis.

Original languageEnglish
JournalActa Radiologica Open
Issue number7
Number of pages5
Publication statusPublished - Jul 2022


Dive into the research topics of 'A rare case of metastatic atypical meningioma that highlights the shortcomings of treatment options at present'. Together they form a unique fingerprint.

Cite this